Sodium fructose diphosphate oral solution is mainly used for the treatment of myocarditis, cardiomyopathy and coronary heart disease. It is also used for the treatment of ischemic-hypoxic encephalopathy, cerebral blood supply deficiency, hyperthermia and hypoxic cranio-cerebral injury. It is also used in the treatment of fatty liver, acute and chronic hepatitis, liver cirrhosis and alcoholic liver disease these diseases. The main adverse reactions are digestive symptoms such as bloating, nausea, burning sensation in the upper abdomen and loose stools, which are usually tolerated and do not require discontinuation of the drug. However, it is contraindicated in people with renal failure and hyperphosphatemia. This product is mainly present in the human body as a cellular metabolite and is able to regulate the activity of various enzymes in glucose metabolism. Therefore, in the process of clinical application, it is beneficial to the energy metabolism and glucose utilization of cells under ischemia and hypoxia, thus it can reduce the damage of ischemic heart muscle.